![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Eligo Bioscience
Main focus: Treatment of bacterial infections
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Paris, France
Website: https://eligo.bio/
Gene editing partnerships: GlaxoSmithKline
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_eligo_24c447285c_857b82895c.png)
Eligo Biosciences seeks to perform precision editing of the human microbiome in order to treat infectious diseases. The company develops engineered phages that deliver CRISPR-Cas systems to pathogenic bacteria. The company has not yet disclosed its lead development programmes, but announced a research and option agreement with GlaxoSmithKline to advance new development candidates from its technology platform.